NASDAQ: BOLDBoundless Bio Inc Stock
$2.50+0.00 (+0%)
Updated Jul 31, 2026
BOLD Price
$2.50
Fair Value Price
-$1.39
Market Cap
$56.16M
52 Week Low
$0.96
52 Week High
$2.79
P/E
-1x
P/B
0.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$55.99M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.63
Operating Cash Flow
-$47M
Beta
0.99
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BOLD Overview
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BOLD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BOLD
Ranked#154 of 460
Ranked#154 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $252.86 | A | |
| $11.21 | A | |
| $114.49 | A |
Be the first to know about important BOLD news, forecast changes, insider trades & much more!
BOLD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BOLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BOLD ($2.50) is overvalued by 279.36% relative to our estimate of its Fair Value price of -$1.39 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BOLD ($2.50) is not significantly undervalued (279.36%) relative to our estimate of its Fair Value price of -$1.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BOLD due diligence checks available for Premium users.
Valuation
BOLD fair value
Fair Value of BOLD stock based on Discounted Cash Flow (DCF)
Price
$2.50
Fair Value
-$1.39
Undervalued by
279.36%
BOLD ($2.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BOLD ($2.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BOLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BOLD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1x
Industry
20.12x
Market
16.06x
BOLD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.65x
Industry
5.23x
BOLD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BOLD's financial health
Profit margin
Revenue
$0.0
Net Income
-$13.6M
Profit Margin
0%
BOLD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$141.0M
Liabilities
$54.6M
Debt to equity
0.63
BOLD's short-term assets ($94.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BOLD's short-term assets ($94.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BOLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.0M
Investing
$14.6M
Financing
$0.0
BOLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BOLD vs Biotech Stocks
Boundless Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.